Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts

Laura P. Serwer, Charles O. Noble, Karine Michaud, Daryl C. Drummond, Dmitri B. Kirpotin, Tomoko Ozawa, Michael D. Prados, John W. Park, C. David James*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Achieving effective treatment outcomes for patients with glioblastoma (GBM) has been impeded by many obstacles, including the pharmacokinetic limitations of antitumor agents, such as topotecan (TPT). Here, we demonstrate that intravenous administration of a novel nanoliposomal formulation of TPT (nLS-TPT) extends the survival of mice with intracranial GBM xenografts, relative to administration of free TPT, because of improved biodistribution and pharmacokinetics of the liposome-formulated drug. In 3 distinct orthotopic GBM models, 3 weeks of biweekly intravenous therapy with nLS-TPT was sufficient to delay tumor growth and significantly extend animal survival, compared with treatment with free TPT (P ≤ .03 for each tumor tested). Analysis of intracranial tumors showed increased activation of cleaved caspase-3 and increased NA fragmentation, both indicators of apoptotic response to treatment with nLS-TPT. These results demonstrate that intravenous delivery of nLS-TPT is a promising strategy in the treatment of GBM and support clinical investigation of this therapeutic approach.

Original languageEnglish (US)
Pages (from-to)1288-1295
Number of pages8
JournalNeuro-oncology
Volume13
Issue number12
DOIs
StatePublished - Dec 2011

Keywords

  • Bioluminescence imaging
  • Glioma
  • Liposome
  • Topotecan
  • Xenograft.

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts'. Together they form a unique fingerprint.

Cite this